Evid Based Complement Alternat Med. 2014;2014:438506. doi: 10.1155/2014/438506. Epub 2014 Dec 23.

Antidepressant-like effects of cordycepin in a mice model of chronic unpredictable mild stress.

Evidence-based complementary and alternative medicine : eCAM

Zhang Tianzhu, Yang Shihai, Du Juan

PMID: 25587342 PMCID: PMC4284936 DOI: 10.1155/2014/438506

Abstract

Cordycepin (3'-deoxyadenosine), a major bioactive component isolated from Cordyceps militaris, has multiple pharmacological activities. This study is attempted to investigate whether cordycepin (COR) possesses beneficial effects on chronic unpredictable mild stress- (CUMS-) induced behavioral deficits (depression-like behaviors) and explore the possible mechanisms. ICR mice were subjected to chronic unpredictable mild stress for 42 consecutive days. Then, COR and fluoxetine (FLU, positive control drug) were administered for 21 consecutive days at the last three weeks of CUMS procedure. The classical behavioral tests, open field test (OFT), sucrose preference test (SPT), tail suspension test (TST), and forced swimming test (FST), were applied to evaluate the antidepressant effects of COR. Then the serotonin (5-HT) and noradrenaline (NE) concentrations in hippocampal were evaluated by HPLC; tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in hippocampal were evaluated, and the proteins of TNF-α, IL-6, NF-κBP65 5-HT2A receptor (5-HT2AR), and brain-derived neurotrophic factor (BDNF) in hippocampal were evaluated by Western blot. Our results indicated that 6 weeks of CUMS exposure induced significant depression-like behavior, with low 5-HT and NE levels, high TNF-α and IL-6 in brain and high hippocampal TNF-α, IL-6, P-NF-κBP65, and 5-HT2AR levels, and low BDNF expression levels. Whereas, chronic COR (20, 40 mg/kg) treatments reversed the behavioral deficiency induced by CUMS exposure, treatment with COR normalized the change of TNF-α, IL-6, 5-HT, and NE levels, which demonstrated that COR could partially restore CUMS-induced 5-HT receptor impairments and inflammation. Besides, hippocampal BDNF expressions were also upregulated after COR treatments. In conclusion, COR remarkably improved depression-like behavior in CUMS mice and its antidepressant activity is mediated, at least in part, by the upregulating BDNF and downregulating 5-HT2AR levels and inflammation in hippocampus.

References

1. Arch Gen Psychiatry. 1980 May;37(5):541-8 - PubMed
2. Annu Rev Neurosci. 2001;24:677-736 - PubMed
3. Mol Med. 2011 Sep-Oct;17 (9-10):893-900 - PubMed
4. JAMA. 2003 Jun 18;289(23):3095-105 - PubMed
5. Trends Pharmacol Sci. 1995 Mar;16(3):105-10 - PubMed
6. Biol Psychiatry. 1998 Mar 1;43(5):315-9 - PubMed
7. Eur J Pharmacol. 2010 Sep 25;643(2-3):232-8 - PubMed
8. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Apr 29;35(3):664-75 - PubMed
9. Rheumatology (Oxford). 2009 Jan;48(1):45-8 - PubMed
10. Naunyn Schmiedebergs Arch Pharmacol. 2008 Feb;376(6):441-8 - PubMed
11. Psychopharmacology (Berl). 1985;85(3):367-70 - PubMed
12. Nat Rev Neurosci. 2008 Jan;9(1):46-56 - PubMed
13. Inflammation. 2014 Aug;37(4):1044-9 - PubMed
14. Brain Res Bull. 2008 Sep 5;77(1):8-12 - PubMed
15. Neuropharmacology. 1977 Jan;16(1):53-5 - PubMed
16. J Neurosci Methods. 1980 Dec;3(2):129-49 - PubMed
17. Psychopharmacology (Berl). 1987;93(3):358-64 - PubMed
18. Arch Int Pharmacodyn Ther. 1977 Oct;229(2):327-36 - PubMed
19. Ann N Y Acad Sci. 2009 Oct;1179:216-28 - PubMed
20. Behav Brain Res. 2012 May 16;231(1):130-7 - PubMed
21. Neurosci Biobehav Rev. 2012 Feb;36(2):764-85 - PubMed
22. Biol Psychiatry. 2009 May 1;65(9):732-41 - PubMed
23. Neurosci Biobehav Rev. 2012 Oct;36(9):2085-117 - PubMed
24. Neurochem Int. 2013 Nov;63(5):465-75 - PubMed
25. Brain Res. 1993 Jun 18;614(1-2):37-44 - PubMed
26. Psychopharmacology (Berl). 1997 Dec;134(4):319-29 - PubMed
27. Neuroscience. 2013 Jun 3;239:157-72 - PubMed

Publication Types

• Journal Article